NCT00500604 - Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension | Biotech Hunter

Enrollment

1,617

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Hypertension

Interventions

DRUG

Irbesartan/hydrochlorothiazide

150/12.5mg tablet and 300/12.5mg tablet

DRUG

Valsartan/hydrochlorothiazide

80/12.5mg tablet and 160/12.5mg tablet

DRUG

Hydrochlorothiazide

12.5 mg administered orally, once daily in the morning

Trial Locations (14)

Sanofi-Aventis Administrative Office, Cairo

Sanofi-Aventis Administrative Office, Hong Kong

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Jakarta

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, Casablanca

Sanofi-Aventis Administrative Office, Karachi

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Singapore

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Bangkok

Sanofi-Aventis Administrative Office, Mégrine

Sanofi-Aventis Administrative Office, Ho Chi Minh City